Correction: Field, M. et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients

Field, Malgorzata; Splevins, Andrew; Picaut, Philippe; Schans, Marcel van der; Langenberg, J.P.; Noort, Daan; Snyder, Daniel; Foster, Keith A.

doi:10.3390/toxins11020115

Cited by 3 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Response rates of AbobotulinumtoxinA by day 7 have shown to vary between 57% and 83% as measured on a 0‐3 point scale among subjects and investigators 54,55 . As much as 61% of subjects still show some measure of continued response up to 6 months postinjection before relapsing, although the clinical effect is minimal at that point 49,57 . In general, similar time to onset and response rates have been demonstrated among OnabotulinumtoxinA, IncobotulinumtoxinA, and AbobotulinumtoxinA, although one study did demonstrate slightly quicker time to onset for AbobotulinumtoxinA 54,55,58 …”

Section: Postulate Imentioning

confidence: 61%

“…These were measured with ELISA and activity measured by EndoPep assays which demonstrated equivalent light chain activity per nanogram of neurotoxin among all three products. Differences in treatment duration of action may, therefore, be due to differences in the actual quantity of neurotoxin molecules injected rather than the LD50 determined potency of the toxin 57 …”

Section: Postulate IVmentioning

confidence: 99%

See 1 more Smart Citation

The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II

Nestor

Arnold

Fischer

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background The literature on botulinum neurotoxin type A (BoNT‐A) is extensive, often contradictory, and confounded by a competitive market of products and research attempting to distinguish brand individuality. Methods A comprehensive review of literature on the principles of BoNT‐A in aesthetics as well as clinical examples. Results In 2017, the Eight Key Clinical Postulates were formulated as a guide for the aesthetic practitioner in understanding BoNT‐A pharmacodynamics and to compare different toxins. These are now updated to include (a) All type A toxins act identically; (b) The mathematical relationship between toxin and receptor is the basis of efficacy, and clinical efficacy is influenced by molecular potency and patient attributes including muscle mass, gender, age, and ethnicity; (c) Efficacy, onset, and duration are functions of “molecular potency” defined as the number of active 150 kDa molecules available for binding; (d) “Molecular potency” is difficult to objectively quantify for commercially available toxins; (e) Up to a point, increased molecular potency decreases time to onset and increases duration of effect, and the “Molecular Potency Quotient” is a construct for comparing molecular potency commercial cost; (f) The area of effect of a toxin injection is dependent upon molecular potency, diffusion (passive), and spread (active); (g) Differing reconstitution volumes; and (h) Increased number of injection sites can affect spread, onset, and duration of effect. Conclusions The principles of BoNT‐A use in aesthetics are complex yet understandable as outlined in the framework of the updated Eight Key Clinical Postulates and serves as a useful tool for providing the most effective treatment and interpreting research on present and future toxin formulations.

show abstract

Section: Postulate Imentioning

confidence: 61%

Section: Postulate IVmentioning

confidence: 99%

The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II

Nestor

Arnold

Fischer

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

show abstract

“…If the amount of the bonded albumin to the mycotoxin is high in the circulation, the displacement may lead to significant changes in its distribution and/or removal of tissue, resulting in toxicity. Moreover, the species differences in albumin binding can help to understand how the toxicity of some mycotoxins (e. g., zearalenone and its metabolites) changes [9,10] …”

Section: Introductionmentioning

confidence: 99%

In Vitro Study of the Interaction between Ochratoxin A and Human Serum Albumin by Spectroscopic and Molecular Docking Methods

Vakili,

Baher,

Vaezi

et al. 2023

ChemistrySelect

View full text Add to dashboard Cite

Ochratoxin A (OA) is a mycotoxin that has a potential risk to human health due to its nephrotoxic, immunotoxic and carcinogenic effects. For these reasons the interaction of ochratoxin A with human serum albumin (HSA) was investigated in physiological media by various techniques such as UV‐Vis, fluorescence (FL), circular dichroism (CD), attenuated total reflection (ATR), differential scanning calorimetry (DSC), atomic force microscopy (AFM) and molecular docking study via Auto Dock‐vina software. The fluorescence intensity of tryptophan in HSA was strongly quenched in the present of OA and the quenching constants and binding constant were valued 108 M−1 and 1.04 M−1, respectively. The CD spectra showed alteration in the secondary structure of HSA in the presence of ochratoxin by reducing the regular alpha helical structure and increasing the beta‐sheet structure. By increasing the concentration of OA to 1.25 μM, the intensity of absorption spectrum at 282 nm was increased, indicating the strong interaction of OA and HSA. The enthalpies of these molecular interaction calculated from DSC analysis indicate OA interaction with HAS is exothermic. The docking calculations showed that the amino acids of Lys190, ASP187, LYS519, ARG186 and ARG428 were interacted with OA by hydrogen bonding.

show abstract

Botulinum Neurotoxins for Relief of Pain Associated with Spasticity

Jabbari

2022

Botulinum Toxin Treatment of Pain Disorders

View full text Add to dashboard Cite

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients

Abstract: The authors wish to make the following corrections to their paper [...]

Cited by 3 publications

References 1 publication

The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II

The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II

In Vitro Study of the Interaction between Ochratoxin A and Human Serum Albumin by Spectroscopic and Molecular Docking Methods

Botulinum Neurotoxins for Relief of Pain Associated with Spasticity

Contact Info

Product

Resources

About